Islatravir is an investigational drug that is being studied to treat and prevent HIV infection. 3,4 Islatravir belongs to a group of HIV drugs called nucleoside reverse transcriptase translocation inhibitors (NRTTIs). NRTTIs use several different methods to block an HIV enzyme called reverse transcriptase. Zobacz więcej Phase: 2b Status: This study has been completed. Locations: Chile, France, United Kingdom, United States Purpose: The purpose of … Zobacz więcej Phase: 2 Status: This study is ongoing, but not recruiting participants. (See note below.) Location: United States Purpose: The purpose of this study is to evaluate the efficacy of oral weekly islatravir in combination with … Zobacz więcej Phase: 2b Status: This study is ongoing, but not recruiting participants. (See note below.) Locations: United States, France, Switzerland Purpose:The purpose of this study is to evaluate the safety of islatravir plus the … Zobacz więcej Phase: 3 Status: This study is ongoing, but not recruiting participants. (In December 2024, this study was placed on partial clinical hold.) Locations: Multiple countries, including United States Purpose: The purpose of this … Zobacz więcej Witryna25 paź 2024 · Islatravir is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation for the treatment of people living with HIV-1 infection in combination with other antiretrovirals.
What can we help you find? - Merck.com
WitrynaMost recently, data in healthy HIV-1-uninfected individuals demonstrated the feasibility of formulating of ISL as an implant. In these studies, levels of intracellular ISL-triphosphate were consistent with the potential for a once-yearly … Witryna1 kwi 2024 · 強力で長時間作用型のISLは、HIV治療と感染予防において「first-in-class」の抗HIV-1治療薬として、ゲームチェンジャーあるいはパラダイムシフトに … hankyu hanshin express singapore
Merck Announces Clinical Holds on Studies Evaluating Islatravir for …
Witryna7 wrz 2024 · A small study from an HIV hospital that has been conducting experimental analytical treatment interruptions (ATIs) as part of research into achieving a functional cure for HIV infection has found that over a period of years, patients who had undergone ATIs had a higher risk of developing non-AIDS-related serious illnesses such as … Witrynaislatravir是默沙东在研的一款新型口服核苷逆转录酶易位抑制剂（NRTTI） ，用于与其他抗逆转录病毒药物联合治疗HIV-1感染者。 这些研究的详细结果将在未来的科学大会 … Witryna20 sty 2024 · This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir … cgangs international pte ltd